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Abstract
Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote treatment 
resistance1–4. This phenomenon has been implicated in chemorefractory small cell lung cancer 
(SCLC) and resistance to targeted therapies5–8, but remains incompletely defined. Here we 
identify a subclass of endogenous retroviruses (ERVs) that engages innate immune signaling in 
these cells. Stimulated 3 Prime Antisense Retroviral Coding Sequences (SPARCS) are oriented 
inversely in 3′UTRs of specific genes enriched for regulation by STAT1 and EZH2. De-repression 
of these loci results in dsRNA generation following IFNγ exposure due to bi-directional 
transcription from the STAT1-activated gene promoter and the 5′ LTR of the antisense ERV. 
Engagement of MAVS and STING activates downstream TBK1, IRF3, and STAT1 signaling, 
sustaining a positive feedback loop. SPARCS induction in human tumors is tightly associated with 
MHC class 1 expression, mesenchymal markers, and downregulation of chromatin modifying 
enzymes, including EZH2. Analysis of cell lines with high inducible SPARCS expression reveals 
strong association with an AXL/MET positive mesenchymal cell state. While SPARCS high 
tumors are immune infiltrated, they also exhibit multiple features of an immune suppressed 
microenviroment. Together, these data unveil a subclass of ERVs whose de-repression triggers 
pathologic innate immune signaling in cancer, with important implications for cancer 
immunotherapy.
Resistant SCLC undergoes a mesenchymal state switch induced by RAS/MET signaling or 
chemotherapy (e.g. H69M or H69AR subpopulations derived from H69 cell line) 
(Supplementary Fig. 1a)9,10. We noted enhanced innate immune and RAS signaling in 
H69M cells, including elevated phosphorylated-TBK1 (pTBK1), pIRF3, IKKε and NF-κB 
gene sets, and multiple secreted cytokines/chemokines (Figs. 1a,b and Supplementary Fig. 
1b,c). TBK1 activity was preferentially increased in additional mesenchymal SCLC cell 
lines (Supplementary Fig. 1d, e), and subpopulations of human and murine RbL/L/p53L/L 
SCLC tumors (Fig. 1c and Supplementary Fig. 1f–h). Because H69M cells also attracted T 
cells and monocytes (Supplementary Fig. 2a–e), we explored immune checkpoint activation. 
Cañadas et al. Page 2
Nat Med. Author manuscript; available in PMC 2019 January 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
This identified a PD-L1high, CD44high fibroblastic subpopulation responsible for pTBK1 and 
cytokine/chemokine production (Fig. 1d–f and Supplementary Fig. 3a, b).
H69M PD-L1high cells reverted phenotypically in culture and were genomically similar to 
parental H69 cells (Supplementary Fig. 3c, d), suggesting an epigenetic mechanism of innate 
immune activation. Since endogenous retroviruses (ERVs) undergo epigenetic silencing, we 
examined expression of a recently described ERV panel11,12. H69M-PD-L1high cells 
exhibited marked upregulation of MLT1C49 (Fig. 1g), an ERV poised to generate dsRNA 
due to antisense orientation in the 3′UTR of TRIM22, a STAT1 target gene13. Transfection 
of a 3′UTR construct containing this antisense ERV was sufficient to induce cytokine and 
PD-L1 expression in H69M-PD-L1low cells (Fig. 1h and Supplementary Fig. 4a, b), and in 
293T cells (Supplementary Fig 4c). Conversely, siRNA mediated knockdown of MLT1C49 
partially inhibited CXCL10 and CCL2 expression in H69M-PD-L1high cells (Fig. 1i and 
Supplementary Fig. 4d), validating a direct role in this innate immune phenotype, but 
suggestive of redundancy.
We therefore intersected all antisense 3′UTR ERVs from Ref Seq with H69M upregulated 
genes (Supplementary Dataset 1)9, to identify additional ERV family members in this 
mesenchymal state with this unique genomic feature. This analysis identified TRIM22/
MLT1C49 and 14 other genes/ERVs including TRIM38 which contained two (MLT1J, 
MLT1A), the majority of which were specifically induced in H69M-PD-L1high cells (Fig. 1j 
and Supplementary Fig. 5a). Similar to TRIM22, many of these genes contained STAT1 
motifs and/or binding sites13,14 in their promoters (Supplementary Fig. 5b), which suggested 
inducibility by the IFNγ or other STAT1-activating factors already present in H69M 
conditioned media (Fig. 1b, f). Indeed, in contrast to H69 cells IFNγ stimulation of the 
additional mesenchymal subpopulation, H69AR, induced expression of most, but not all of 
these genes/ERVs, (Supplementary Fig 5c) validating a role for STAT1 mediated regulation. 
Conversely, IL32/THE1D and F3/MLT1I were inducible by IFNγ in H69AR cells, but not 
upregulated in H69M-PD-L1high cells (Fig. 1j and Supplementary Fig. 5a, c), suggesting 
some differences in transcriptional state between mesenchymal subclones. Regardless, these 
studies uncovered a wider set of genes with 3′ antisense ERVs preferentially expressed in 
the mesenchymal cell state and regulated by STAT1 signaling. Because of the unique ability 
of interferons to trigger their expression, create dsRNA via bidirectional transcription, and 
spark feed-forward innate immune signaling, we term these ERVs Stimulated 3 Prime 
Antisense Retroviral Coding Sequences (SPARCS).
ERV dsRNAs are sensed by the RIG-1/MDA5-MAVS signaling pathway or reverse-
transcribed and detected via the cGAS-cGAMP STING pathway15. Indeed, we observed 
STING upregulation and increased cytoplasmic MLT1C49 dsDNA in H69M PD-L1high cells 
(Supplementary Fig. 5d–f). MAVS or combined MAVS/STING deletion in H69M cells 
strongly impaired TBK1 and IRF3 phosphorylation (Fig. 1k), decreased multiple cytokines/
chemokines, including CXCL10, CCL5, and CCL2 (Fig. 1l, m) and suppressed T cell and 
monocyte attraction (Supplementary Fig. 6a, b). Deletion of MAVS and/or STING also 
reverted the mesenchymal phenotype, increasing E-cadherin and decreasing Vimentin 
expression (Fig. 1k and Supplementary Fig. 6c,d). Thus, ERV sensing of SPARCS directly 
contributes to this cellular state.
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IFNγ also induced robust PD-L1 expression in H69AR cells, suggesting that differential 
chromatin accessibility could underlie this responsiveness (Fig. 2a). Indeed, even a 10 min 
IFNγ pulse in H69AR, but not H69 cells, resulted in marked induction of TRIM22 and 
MLT1C49, correlating with PD-L1 mRNA and cytokine/chemokine secretion (Fig. 2b, c and 
Supplementary Fig. 7a, b). H69AR cells showed specific gain of chromatin accessibility 
around SPARCS loci, but not PD-L1, CXCL10 or CCL2 (Fig. 2d and Supplementary Fig. 
7c). Because H69M and H69AR cells downregulated EZH216 (Fig. 2e), we examined 
whether EZH2 is involved in silencing SPARCS. EZH2 inhibitor treatment of H69 cells over 
6 days enhanced similar IFNγ induced cytokines (Fig. 2f), and de-repressed the same 
SPARCS as in H69AR cells (Fig. 2g and Supplementary Fig. 7d). Thus, SPARCS loci are 
normally silenced and protected from IFN-induced expression by EZH2, but de-repressed in 
mesenchymal H69 subpopulations.
We next wondered if SPARCS promote positive feedback signal amplification. We detected 
high levels of dsRNA preferentially produced from MLT1C49, MLT1J and MLT1A in 10 
min IFNγ pulsed H69AR cells, even after 24 h (Fig. 2h). TAG-aided sense/antisense 
transcript detection (TASA-TD) PCR17 confirmed that dsRNA resulted from bidirectional 
transcription of MLT1C49, MLT1J, and MLT1A (Supplementary Fig. 8a). IFNγ pulse 
treatment activated and sustained pTBK1 and pIRF3 in addition to pSTAT1 in H69AR but 
not H69 cells (Fig. 2i), which further amplified SPARCS expression, pTBK1, and its 
effector cytokines over time (Fig. 2j and Supplementary Fig. 8b, c). Transfection of the 
dsRNA mimic Poly(I:C) induced type I/II IFNs in H69AR cells (Supplementary Fig. 8d) and 
direct IFNα/β exposure or Poly(I:C) itself induced SPARCS (Supplementary Fig. 8d, e), 
consistent with positive feedback induced by dsRNA and type I IFN. Furthermore, exposure 
of untreated H69AR cells to IFNγ primed conditioned medium activated TBK1 and STAT1 
and induced CXCL10, IFNβ and ERV expression (Supplementary Fig. 9a–d). These data 
confirmed feedforward signaling downstream of SPARCS activation (Supplementary Fig. 
9e). As expected, treatment with the JAK1/2 inhibitor Ruxolitinib disrupted this circuit, 
whereas TBK1/IKKε inhibition with MRT67307, partially inhibited downstream CXCL10 
expression (Supplementary Fig 9f–h). Finally, MAVS deletion also downregulated multiple 
cytokines/chemokines following Poly(I:C) or low dose IFNγ pulse treatment, especially 
when co-deleted with STING (Fig. 2k–m, Supplementary Fig. 9i, j), and impaired 
tumorigenicity in nude mice (Fig. 2n).
To determine the broader relevance of SPARCS and to begin to explore the relationship to 
immune contexture, we next ranked expression of a signature comprised of the 15 SPARCS-
containing genes across the Cancer Genome Atlas (TCGA) (Pancan12, n=3602 tumors)18 
using single sample gene set enrichment analysis (ssGSEA)19 (Fig. 3a and Supplementary 
Fig. 10 a, b). Top gene sets co-enriched with SPARCS-containing genes (p<0.01, 
FDR<0.01) included epigenetic, TNF/NF-κB, inflammation/innate immunity, and RTK/
KRAS signaling (Fig. 3a and Supplementary Dataset 2), also observed in the Cancer Cell 
Line Encyclopedia (CCLE) (Supplementary Fig. 11a and Supplementary Dataset 2). In 
contrast, none of these signatures correlated with a control gene set derived by intersecting 
3′ UTR antisense ERVs with H69M downregulated genes (Supplementary Fig. 11b and 
Supplementary Dataset 3). The SPARCS high state also co-associated with mutations on 
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chromosome 3p, including PBRM1 and SETD2, as well as oncogenic KRAS in CCLE 
(Supplementary Fig. 12a, b and Supplementary Dataset 4).
At the gene level, SPARCS-containing gene expression correlated with markers of T cell and 
myeloid infiltration uniquely in TCGA (Supplementary Fig. 12c and Supplementary Dataset 
2). In both CCLE and TCGA datasets SPARCS associated with expression of MHC, 
APOBEC, immune checkpoint, and EMT genes (Supplementary Fig. 12c, d and 
Supplementary Dataset 2). Expression of EZH2, DNMT3A, SETD2 and multiple SWI/SNF 
genes inversely correlated with SPARCS (Supplementary Fig. 12c, d and Supplementary 
Dataset 2). We next intersected the top 1000 genes from TCGA and CCLE, to isolate robust 
cancer cell autonomous genes co-regulated with SPARCS (Fig. 3b and Supplementary 
Dataset 5). This identified B2M as the top ranked gene, followed by multiple MHC class 1 
genes20, cytosolic RNA sensors. and antigen processing machinery, all markers of a virally 
infected state (Fig. 3b and Supplementary Dataset 5). TGFB1 and AXL were also top hits 
(Fig. 3b and Supplementary Dataset 5).
High expression of the SPARCS-containing gene signature in TCGA was enriched in 
distinct cancer histologies beyond SCLC, including clear cell renal (KIRC), lung 
adenocarcinoma (LUAD), head/neck squamous (HNSC), and glioblastoma (GBM) (Fig. 3c). 
SPARCShigh CCLE lines also included triple negative breast cancer (TNBC), and exhibited 
high relative expression of AXL, MET, VIM, TGFB1 and CD44, and low EZH2, SETD2 
and SWI/SNF component expression (Supplementary Fig. 13a and Supplementary Dataset 
6). SPARCShigh cell lines exhibited mesenchymal morphology and elevated AXL, MET and 
Vimentin relative to SPARCSlow cells (Fig. 3d and Supplementary Fig. 13b). Similar to the 
H69 model, SPARCShigh cells exhibited increased STING, but not MAVS levels (Fig. 3d 
and Supplementary Fig. 13a). IFNγ pulse treatment of SPARCShigh cells significantly 
induced MLT1C49, CXCL10 and PD-L1 expression relative to SPARCSlow cells, and 
inducible surface PD-L1 correlated with high baseline CD44 expression (Fig. 3e and 
Supplementary Fig. 14a).
We next used immune cell GSEA21 to assess whether certain immune infiltrates might be 
associated with elevated SPARCS-containing gene expression in TCGA (Fig. 4a). Despite 
markers of cytotoxic T cells and an adaptive immune response (AIR), the top associated 
signatures were innate immune response (IIR) and myeloid derived suppressor cells 
(MDSC), followed by neutrophils and macrophages (Fig. 4a). Grouping of TCGA tumors 
into discrete SPARCS high/low categories (Supplementary Fig. 14b), confirmed robust and 
significant association of SPARCShigh tumors with these signatures (Fig. 4b, c). Consistent 
with T cell and myeloid cell chemotaxis, CXCL10 and CCL2 gene expression in primary 
tumors was tightly associated with the SPARCShigh state (Fig. 4d and Supplementary 
Dataset 6). Thus, myeloid cell infiltration may further contribute to an immunosuppressed 
microenvironment in SPARCShigh tumors.
Finally, we utilized ex vivo culture of patient-derived organotypic tumor spheroids (PDOTS) 
with autologous tumor infiltrating lymphocytes22 to explore translational relevance of these 
findings. Using multiplexed immunofluorescence we confirmed T cell infiltration of two 
different KRAS mutant non-small lung cancer specimens (Fig. 4e), one with SPARCShigh 
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features including SETD2 inactivation and APOBEC mutation pattern (NSCLC-1), and the 
other with STK11/TP53 co-mutation (NSCLC-2) and T cell localization between tumor 
nests. IFNγ or Poly(I:C) treatment of NSCLC-1 PDOTS markedly enhanced production of 
multiple cytokines/chemokines, especially CXCL10, and sensitized them to ex vivo PD-1 
blockade with nivolumab, in contrast to NSCLC-2 (Fig. 4f–h and Supplementary Fig. 14c–
e). Thus, IFN signaling associated with the SPARCShigh state can be directly ascertained 
from patient samples and may promote sensitivity to PD-1 blockade.
Here we identify SPARCS as a novel subclass of ERVs silenced by EZH2 and poised to 
undergo positive feedback signal amplification due to antisense localization in 3′ UTRs of 
IFN stimulated genes. Whereas prior reports utilized DNMT inhibition to uncover ERVs 
more generally to induce a state of viral mimicry11,12, our data reveal that mesenchymal 
tumor subpopulations with high AXL/MET expression and low EZH2 levels trigger 
expression of a specific set of ERVs when exposed to IFNγ, with important implications for 
understanding tumor heterogeneity and oncogenesis. This SPARCS high state was also 
associated with downregulation of multiple SWI/SNF components and enriched in RCC, 
potentially contributing to the immunogenicity recently reported following PBRM1 
inactivation23,24. While SPARCS expression promotes MHC class 1 upregulation and T cell 
infiltration, activation of immune checkpoints and myeloid infiltration may promote tumor 
immune suppression, similar to a chronic virally infected state. Therapeutically, this may 
have important implications for drug combinations with PD-1 blockade. For example, in 
addition to blocking specific chromatin regulators23–25, therapies that hyperactivate JAK 
signaling26 or target TBK122,26 could alter SPARCS physiology to favor response.
Methods
Patients samples
SCLC and NSCLC human tumor samples were collected and analyzed according to Dana-
Farber/Harvard Cancer Center IRB-approved protocols. These studies were conducted 
according to the Declaration of Helsinki and approved by Dana-Farber and Brigham and 
Women’s Hospital IRBs.
Cell lines
The human SCLC cell lines NCI-H69, H69M, H69AR, NCI-H841, SHP77, NCI-H187, 
NCI-H345 and NCI-H524 were obtained from the laboratory of Dr. Joan Albanell and were 
authenticated following Short Tandem Repeat (STR) genotyping. Clear cell renal carcinoma 
(ccRCC) cell lines A704, A498, 786-O, 769-P and Caki-2 were obtained from the laboratory 
of Dr. William G. Kaelin Jr. and were authenticated following STR genotyping. HCC44 cell 
line was obtained from Broad Institute and was authenticated following STR genotyping. 
Jurkat T cells, THP-1 monocytes, NCI-H196, MDA-MB-231, HCC1143, MDA-MB-468, 
NCI-H522, T47D, MDA-MB-453, NCI-H1436, NCI-H2081 and 293T cells were obtained 
from the American Type Culture Collection (ATCC) (Rockville, MD) and used for all 
experiments before reaching 10 passages.
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H69, H69M, H69AR, H841, SHP77, H187, H345, H524, H196, HCC44, MDA-MB-231, 
MDA-MB-453, MDA-MB-468, T47D, HCC1143, H522, H1436, H2081, THP-1, Jurkat and 
769-P were cultured in RPMI-1640 (Thermo Fisher Scientific, #11875-119) containing 10% 
FBS (Gemini Bio-products, #100-106) and 1X pen-strep (Gemini Bio-products, #400-109). 
786-O, A498 and 293T were maintained in Dulbecco’s Modified Eagles Medium (DMEM) 
(Thermo Fisher Scientific, #11965-118) containing 10% FBS and 1X pen-strep. Caki-2 cells 
were maintained in McCoy’s 5A medium (Life Technologies #16600108) supplemented 
with 10% FBS and 1X Penicillin-Streptomycin. A704 cell lines was maintained in Eagle’s 
Minimum Essential Medium (EMEM) (Sigma, #M4780) supplemented with 2mM 
Glutamine (Life Technologies, #25030081), 1% Non Essential Amino Acids (NEAA) (Life 
Technologies, #11140-050), 1mM Sodium pyruvate (Life Technologies, #11360-070), 15% 
FBS and 1X Penicillin-Streptomycin.
Immunohistochemical staining
After deparaffinizing tissue blocks, antigen retrieval was achieved by wet autoclave (121 
degrees Celsius, 15 min) in Antigen Retrieval Solution, pH 9 (Dako, S2367) for p-TBK1. In 
order to block endogenous peroxide enzyme, tissue sections were incubated for 30 minutes 
using Peroxidase-Blocking Solution (Dako, S2023). Then, to block non-specific background 
staining, tissue sections were incubated for 20 minutes with Protein Block (Dako, X0909) 
(human tissue) or Mouse on Mouse blocking reagent (Vector Laboratories, MKB-2213) 
(mouse tissue). Primary antibody specific for pTBK1 (Cell Signaling Technology, 5483; 
1:50 dilution) was applied, and slides were incubated for 16 hours at 4°C. Visualization was 
achieved using EnVision™+/HRP, Rabbit (Dako, K4003) for pTBK1, followed by 
diaminobenzidine (Dako, K3468), and hematoxylin counterstain. Expression levels of 
pTBK1 were evaluated by two pathologists who were blinded to other data.
SCLC GEM model
All mouse experiments were conducted in accord with a Dana-Farber Cancer Institute 
Institutional Animal Care and Use Committee (IACUC) approved protocol. Primary tumor 
and metastasis tissue sections used in this study were from the genetically engineered mouse 
(GEM) model of SCLC consisting of the RbL/L/p53L/L allelic genotype 27. A total number 
of 24 slices of 1 mm thickness were collected providing a sufficient number to cover the 
lung volume. Tumor volume per animal was quantified using 3D Slicer by manual 
quantification of at least 8 consecutive axial image sequences. MRI was performed to follow 
tumor volume and weights were monitored bi-weekly. Mice were euthanized and lungs and 
livers were perfused with 10% formalin, stored in fixative overnight, and embedded in 
paraffin. For further staining with hematoxylin and eosin (H%E) and antibodies, sections of 
5 μm were cut.
Immunoblotting, antibodies and ELISA
Protein was isolated from cell lines and measured by BCA (Pierce Biotechnology). Protein 
extracts were subjected to polyacrylamide gel electrophoresis using the 4%–12% NuPAGE 
gel system (Invitrogen, Carlsbad, CA), transferred to PVDF (Millipore) membranes, and 
immunoblotted using antibodies that specifically recognize TBK1 (#3013), S172 pTBK1 
(#5483), pERK1/2 (#4370), ERK1/2 (#9107), S473 pAKT (#4060), AKT (#9272), S396 
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pIRF3 (#4947), IRF3 (#4302), Y701 pSTAT1 (#9171), STAT1 (#9172), AXL (#8661), 
EZH2 (#5246), STING (#13647), MAVS (#3993), E-Cadherin (#3195), Vimentin (#5741), 
β-Actin (#4970), Tubulin (#2144), Lamin A/C (#2032) (Cell Signaling Technologies, 
Danvers, MA) and IKKε (#I4907) (Sigma-Aldrich, St. Louis, MO).
Secondary antibodies were from LICOR Biosciences (Lincoln, NE): IRDye 800CW Goat 
anti-Mouse IgG (H + L) (#926-32210), IRDye 800CW Goat anti-Rabbit IgG (H + L) 
(#926-32211). LICOR blocking buffer (#927-40000) was used to dilute primary and 
secondary antibodies, with the exception of phosho-specific antibodies, which were diluted 
in HIKARI Signal Enhancer Solutions 1 and Solution 2 (Nacalai USA, Inc. # NU00101). 
Imaging of blots and quantitation of bands was performed using the LICOR Odyssey 
system.
Proteome Profiler™ Human Cytokine Array Kit (#ARY005B) and CXCL10 ELISA 
(#DIP100) (R&D Systems, Minneapolis, MN), were performed according to manufacturer’s 
instructions. For cytokine array, conditioned media (CM) from SCLC cells at basal 
conditions was collected after 48 and 72 hours. For CXCL10 ELISA, CM from IFN–γ 
pulsed cells was collected after 72 hours.
Microfluidic culture
Microfluidic device design and fabrication was performed as described 28, with 
modifications of device dimensions to accommodate larger volumes of media. DAX-1 3D 
cell culture chip (AIM Biotech, Singapore) was also used for select studies. H69, H69M and 
H69AR cell suspensions (2.5 × 104 cells) were pelleted and resuspended in type I rat tail 
collagen (Corning, Corning, NY) at a concentration of 2.5 mg/mL following addition of 10× 
PBS with phenol red with pH adjusted using NaOH. pH 7.0–7.5 confirmed using PANPEHA 
Whatman paper (Sigma-Aldrich, St. Louis, MO). The cell-collagen mixture was then 
injected into the center gel region of the 3D microfluidic culture device. Microfluidic culture 
devices were designed with a central region containing the cell-collagen mixture, surrounded 
by 2 media channels located on either side formed by bonding a coverslip to a patterned 
polydimethylsiloxane (PDMS) substrate. Collagen hydrogels containing cells were 
incubated 30 minutes at 37°C and then hydrated with media with or without 2.5 × 104 cells 
CFSE labeled Jurkat T cells and THP1 monocytes in the side media channels. Jurkat T cells 
or THP1 monocytes were labeled with the CFSE Cell Division Tracker Kit (BioLegend, San 
Diego, CA) following manufacturer’s instructions. Following 48 hours of incubation, images 
were captured on a Nikon Eclipse 80i fluorescence microscope equipped with Z-stack 
(Prior) and CoolSNAP CCD camera (Roper Scientific). Image capture and analysis was 
performed using NIS-Elements AR software package. Whole device images were achieved 
by stitching in multiple captures. Cell quantitation was performed by measuring total cell 
area of CFSE dye.
Flow cytometry analysis and cell sorting
Cells were stained with anti–PD-L1 (Biolegend, Cat# 329717), anti-CD44 (Biolegend, Cat# 
103011) or isotype IgG control antibodies (Biolegend, Cat# 400326 and Cat#400611), in 
PBS containing 2% FBS for analysis and cell sorting. Briefly, cells were washed and further 
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incubated with the indicated antibodies at 2 μg/mL. After 3 washes with PBS, cells were 
resuspended in PBS containing 2% FBS and analyzed on BD FACSCanto II or sorted to 
>95% purity using a BD FACSAria II. Levels were compared with isotype control 
antibodies. PD-L1 and CD44 mean fluorescence intensity (MFI) was normalized to isotype 
control. The data analyses were performed with FlowJo software (TreeStar).
Cytokine profiling
Multiplex assays were performed utilizing the bead-based immunoassay approach Bio-Plex 
Pro™ Human Cytokine 40-plex Assay (Cat# 171AK99MR2) on a Bio-plex 200 system 
(Cat# 171000201) (Bio-Rad Laboratories, Hercules, CA) and the Human Cytokine/
Chemokine Maganetic Bead Panel (Cat# HCYTMAG-60K-PX30) on a Luminex MAGPIX 
system (Merck Millipore, Billerica, MA). Conditioned media concentration levels [pg/ml] of 
each protein were derived from 5- parameter curve fitting models. Fold changes relative to 
the corresponding control were calculated and plotted as log2FC. Lower and upper limits of 
quantitation (LLOQ/ULOQ) were imputed from standard curves for cytokines above or 
below detection.
Quantitative RT-PCR
Total cellular RNA was extracted using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) 
according to manufacturer’s instructions. After extraction, 1 μg total RNA was used to 
generate cDNA with the SuperScript III First-Strand Synthesis SuperMix for qRT-PCR kit, 
which includes both oligo-dT and random primers (Thermo Fisher Scientific, Waltham, 
MA). Quantitative reverse transcription PCR (qRT-PCR) of the indicated genes 
(Supplementary Dataset 7) was performed using SYBR green PCR Master Mix (Applied 
Biosystems, Foster City, CA) and the Applied Biosystems 7300 Fast real-time PCR system 
and software. The relative expression was normalized with the expression of the 
housekeeping gene 36B4. The sequences of primers used have been listed in Supplementary 
Dataset 7.
Nuclear/cytoplasmic fractionation and DNA purification
Nuclear/cytoplasmic fractions from H69M PD-L1low and H69M PD-L1high cells were 
obtained according to the manufacturer’s instructions (Nuclear/Cytosol Fractionation Kit, 
#K266-25, BioVision). Cleared extracts were treated with 20 mg/mL RNase A (Qiagen) for 
30 minutes at 37ºC, 20 mg/mL Proteinase K (Thermo Fisher Scientific, Waltham, MA) for 1 
hour at 55ºC and then extracted with phenol:chloroform (Invitrogen, Carlsbad, CA). DNA 
was isopropanol precipitated, washed with 70% Ethanol, air-dried and resuspended in water.
Digital droplet PCR
PCR reactions (25 μl) that comprised ddPCR™ Supermix for Probes, custom-made Taqman 
primer/probe mix and appropriate DNA template were prepared in a 96-well PCR plate and 
subsequently loaded onto the Automated Droplet Generator (Bio-Rad). After droplet 
generation, the new 96-well PCR plate was heat-sealed, placed on a conventional thermal 
cycler, and amplified to the end-point. After PCR, the 96-well PCR plate was read on the 
QX100 droplet reader (Bio-Rad). Analysis of the ddPCR data was performed with 
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QuantaSoft analysis software (Bio-Rad) that accompanied the droplet reader. The sequences 
of primers used have been listed in Supplementary Dataset 7.
ERV over-expression and knockdown
The 3′UTR TRIM22 region including the antisense MLT1C49 ERV was amplified with 
PCR from H69M cells RNA and cloned into pLX_307 vector. H69M PD-L1low cells were 
transfected by nucleofection (Amaxa™ 4D-Nucleofector X Unit) according to the 
manufacturer’s instructions (Lonza, Basel, Switzerland). RNA was isolated after 24 hours 
and conditioned media after 72 hours post-nucleofection with this construct versus pLX 
307-GFP. 293T cells, which lack STING, were transduced with these same constructs using 
X-treme Gene 9 (Roche, Basel, Switzerland) according to the manufacturer’s instructions, 
followed by isolation of both RNA and conditioned media after 72 hours to maximize 
sensitivity.
For knockdown experiments, H69M PD-L1high cells were transfected with a scrambled 
negative control siRNA or two siRNAs targeting MLT1C49 (each 40nM) using 
Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific, Waltham, MA). RNA was 
isolated after 72h post-transfection to ensure knockdown.
CRISPR-Cas9 gene editing and lentiviral infection
Oligonucleotides coding for guide RNAs that target STING and MAVS genes were chosen 
from the Avana library and the Brunello library 29. A non-targeting sgRNA from the Gecko 
library v2 was used as a dummy sgRNA for control 30. Lenti CRISPRv2 vectors were cloned 
as previously described 30,31. sgRNA target sequences are described on Supplementary 
Dataset 7.
293T cells were transduced with lentiCRISPRv2 using X-treme Gene 9 (Roche, Basel, 
Switzerland) according to the manufacturer’s instructions. On day 2, target cells were 
seeded, and allowed to adhere overnight. On day 3 the supernatant of transduced 293T cells 
was collected and added to the target cells through a 0.45 μm filter. Supernatant from 
transduced 293T cells was again collected and added to target cells on day 4. On day 5, 
puromycin or blasticidin was added to select infected cells (for four days).
Compounds and treatments
Recombinant human IFN-γ (#285-IF) IFN-α (#11100-1) and IFN-β (#8499-IF) proteins 
were purchased from R&D Systems (Minneapolis, MN) and reconstituted in sterile, 
deionized water. MRT67307 and Ruxolitinib were synthesized and purchased from Shanghai 
Haoyuan Chemexpress Co. Both drugs were reconstituted at 10 mM in DMSO and stored at 
−20ºC. GSK126 (#S7061) was purchased from Selleck chemicals (Houston, TX) and 
reconstituted at 5 mM in DMSO and stored at −20ºC.
For IFN pulse experiments, cells were pulsed 10 minutes with IFN–γ (200 ng/mL or 10 ng/
mL), IFN-α (10 000 U/mL) or IFN-β (10 000 U/mL), extensively washed, and chased in 
fresh media for an additional 24, 48 or 72 hours. To test drug effects on gene expression or 
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protein secretion, IFN–γ pulsed H69AR cells were treated with DMSO, 1μM MRT67307 or 
100 nM Ruxolitinib for 24, 48 and 72 hours.
For EZH2 inhibition experiments, H69 cells were treated with 5 μM GSK126 for 6 days. 
Drug was replenished every 3 days with both suspension and adherent cells carried each 
time. After the GSK126 treatment period, equal numbers of DMSO-treated and GSK126-
treated cells were exposed to either H2O or 200 ng/mL IFN-γ for 24 hours before harvesting 
of RNA or conditioned media (CM).
dsRNA enrichment
For dsRNA enrichment, RNA was first treated or not for 30 min with 50 μg/ml RNase A 
(Qiagen, Hilden, Germany) in high-salt concentration (NaCl, 0.35 M) to prevent dsRNA 
degradation. After treatment, RNase A was removed by ethanol precipitation and the 
product was resuspended in sterile water. Next, RNase A-treated RNA was 
immunoprecipitated (IP) using the J2 dsRNA-specific antibody (English and Scientific 
Consulting Kft, Szirák, Hungary). In brief, the product of 9 μg of RNase A-treated RNA was 
incubated in binding buffer (150 mM NaCl, 50 mM TRIS pH8.0, 1 mM EDTA, 1% NP-40) 
with 5 μg of J2 antibody rotating overnight at 4°C. J2-bound dsRNA was incubated in biding 
buffer with 25 μL of Dynabeads Protein G (Thermo Fisher Scientific, Waltham, MA) for 4 
hours at 4°C, followed by 5 washes in cold binding buffer. RNA was then extracted with 
TRIzol Reagent and expression levels of indicated genes were analyzed by qRT-PCR.
Enrichment of dsRNA over ssRNA was then calculated by normalizing the delta Ct of ERVs 
(dsRNA) against beta-actin (ssRNA).
First strand cDNA synthesis and strand specific PCR for detection of sense and antisense 
ERV transcripts using TASA-TD methodology
Components from the SuperScript III First-Strand Synthesis System for RT-PCR (Thermo 
Fisher Scientific, Waltham, MA) were adapted to perform reverse transcription with RNA 
from H69AR previously pulsed with IFN–γ 10 minutes. For first strand cDNA synthesis 
400 ng RNA was used for β-actin, MLT1C49, MLT1A and MLT1J. 1μM of a gene specific 
primer ligated to a TAG-sequence not specific for the human genome (GSP sense/antisense 
(RT) TAG) was implemented in the reaction. RNA and primers were preheated at 65°C for 
5min. For the total reaction: the GSP-TAG, 0.5mM dNTP, 5mM MgCl2, 10mM DTT, 40U 
RNaseOUT, 100U SuperScriptIII® RT and 240ng Actinomycin D (Sigma-Aldrich, St. 
Louis, MO) were added with the RNA for a 20μl reaction. Synthesis was performed at 50°C 
for 50 min and terminated at 85°C for 5 min. RT with extremely low intrinsic RNase H 
activity (for cleavage of RNA from RNA/DNA duplexes) and Actinomycin D was added to 
prevent second strand cDNA RT resulting in antisense artifacts 32. After cDNA synthesis 2U 
recombinant RNase H was added to each reaction and incubated 20 min at 37°C. Finally, the 
first strand cDNA mix was ethanol precipitated and resuspended in 10 μl sterile water. 
Afterwards gene and strand specific qRT-PCR was performed using SYBR green PCR 
Master Mix. To amplify sense cDNA and antisense cDNA a TAG-primer and GSP sense-
primer and a TAG-primer and GSP antisense-primer were used, respectively. We performed 
sense and antisense specific qRT-PCR using both sense and antisense cDNA of beta-actin as 
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an internal negative control that was previously demonstrated to have no antisense transcript 
33
. The sequences of primers used have been listed in Supplementary Dataset 7.
Poly(I:C) treatment
For Poly(I:C) dsRNA treatment experiments, H69ARsgCTRL and H69ARsgMAVS cells 
were plated in RPMI media, transfected with 0.5 μg/mL Poly(I:C) HMW (InvivoGen, Sand 
Diego, CA) using XtremeGene HP transfection reagent (Sigma-Aldrich, St. Louis, MO) and 
cultured for 72 hours. On day 3 after transfection, conditioned media was recovered and 
CXCL10 protein expression was quantified using Human CXCL10/IP-10 Quantikine ELISA 
kit (R&D Systems, Minneapolis, MN). RNA was extracted and expression levels of relevant 
genes were analyzed by qRT-PCR.
Xenograft studies
H69AR xenograft model was established by subcutaneous (s.c.) injection of 2.5 × 105 
sgCTRL or sgMAVS-H69AR cells in matrigel (Corning, Corning, NY) into the flank of 
nude mice (Charles River Laboratories, Wilmington, MA). Tumor volume was determined 
from caliper measurements of tumor length (L) and width (W) according to the formula L × 
W2/2. Both tumor size and body weight were measured three times per week.
Multiplexed Immunofluorescence
Multiplex Immunofluorescent staining was performed overnight for approximately 12 hours 
on BOND RX fully automated stainers (Leica Biosystems) as previously described 34. 
Briefly, tissue sections of 5-μm thick FFPE were baked for 3 hours at 60°C before loading 
into the BOND RX. Slides were deparaffinized (BOND DeWax Solution, Leica Biosystems) 
and rehydrated with series of graded ethanol to deionized water. Antigen retrieval was 
performed in BOND Epitope Retrieval Solution 1 (ER1, Leica Biosystems) at pH 6 for 10 
minutes at 98°C. Deparaffinization, rehydration and antigen retrieval were all 
preprogrammed and executed by the BOND RX. Next, slides were serially stained with 
primary antibodies, such as anti-CD8 (clone C8/144B; DAKO, dilution 1:5000). Incubation 
time per primary antibody was 40 minutes. Subsequently, anti-rabbit Polymeric Horseradish 
Peroxidase (Poly-HRP, BOND Polymer Refine Detection Kit, Leica Biosystems) was 
applied as a secondary label with an incubation time of 10 minutes. Signal for antibody 
complexes was labeled and visualized by their corresponding Opal Fluorophore Reagents 
(PerkinElmer) by incubating the slides for 5 minutes. The same process was repeated for the 
following antibodies / fluorescent dyes. Slides were air dried, mounted with Prolong 
Diamond Anti-fade mounting medium (#P36965, Life Technologies) and stored in a light-
proof box at 4 °C prior to imaging. The target antigens, antibody clones, and dilutions for 
markers included in this report and details of controls are listed in Supplementary Table 1.
Image acquisition and analysis—Image acquisition was performed using the Mantra 
multispectral imaging platform (Vectra 3, PerkinElmer, Hopkinton, MA) as previously 
described 34. Areas with non-tumor or residual normal tissue (i.e. residual lymph node) were 
excluded from the analysis. Representative regions of interest were chosen by the 
pathologist, and 5–7 fields of view (FOVs) were acquired at 20× resolution as multispectral 
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images. Image Analysis was performed using the Inform 2.3 Image Analysis Software 
(PerkinElmer, Hopkinton, MA).
Ex vivo culture of patient-derived organotypic tumor spheroids (PDOTS)
PDOTS from human NSCLC resection specimens were generating according to our recent 
publication22. Briefly, fresh tumor specimens were minced and resuspended in media with 
collagenase type IV (Life Technologies, Carlsbad, CA). After digestion, samples were 
strained over 100 μm filter and 40 μm filters to generate S1 (>100 μm), S2 (40–100 μm), and 
S3 (<40 μm) spheroid fractions. S2 spheroid fraction was pelleted and resuspended in type I 
rat tail collagen (Corning, Corning, NY) at a concentration of 2.5 mg/mL. The spheroid-
collagen mixture was then injected into the center gel region of the 3D microfluidic culture 
device. Collagen hydrogels containing PDOTS were hydrated with media and treated with 
anti-PD-1 (Nivolumab, 100 μg/mL), IFNγ (200 ng/mL), Poly (I:C) (0.5 μg/mL) or 
combination (Nivolumab + IFNγ, Nivolumab + Poly (I:C)). The number of Live/Dead cells 
in each treatment condition was determined by Trypan Blue Exclusion method and plotted 
as percentage of viability. Nivolumab (Opdivo; Bristol-Myers Squibb) was obtained from 
the DFCI pharmacy.
OncoPanel assay
Somatic mutations, copy number variations and structural variants in parental H69 cells and 
H69M-PD-L1low/H69M-PD-L1high subpopulations were evaluated by performing the 
OncoPanel assay from the Center for Advanced Molecular Diagnostics from Brighman and 
Women’s Hospital.
This OncoPanel assay surveys exonic DNA sequences of 300 cancer genes and 113 introns 
across 35 genes for rearrangement detection. DNA was isolated from cell lines and analyzed 
by massively parallel sequencing using a solution-phase Agilent SureSelect hybrid capture 
kit and an Illumina HiSeq 2500 sequencer.
The 300 genes are listed in Supplementary Dataset 8.
Genomic analysis and SPARCS gene set derivation
The H69 vs H69M expression microarray data analyzed in this study were obtained from the 
publicly available dataset GSE451209. The list of 452 top genes upregulated and 
downregulated in H69M versus H69 is available in Supplementary Dataset 1.
ChIP-seq data for STAT1 and IRF1 data on CD14+ monocytes were retrieved from GEO 
database (GSE43036). Replicates data for each ChIP were aggregated into a single wiggle 
file and visualized in IGV genome browser at the locus of TRIM22 gene35.
For SPARCS gene set derivation, genomic coordinates of all 3′UTR from NCBI RefSeq 
transcripts were intersected with all repeat elements that are 50bp or longer and have its 
family name containing a string ‘ERV’ from UCSC Repeat Masker. Those 5880 3′UTRs 
that overlap with any ERVs were collapsed to the gene level (Supplementary Dataset 1). 
Those 1,080 unique genes were further used to find overlaps with differentially expressed 
gene from an analysis comparing H69M vs H69. Of 452 significantly upregulated genes 
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(adjP<1E–4 and logFC>2) in H69M, 22 genes were found overlapped (Supplementary 
Dataset 1). From this list of 22 overlapping genes, we manually curated them using a UCSC 
genome browser (https://genome.ucsc.edu). Of the 22 ERVs, 15 of these were encoded in 
antisense orientation which were chose for further studies.
As we identified only 86 genes at the same threshold, the same number of genes (452) most 
significantly downregulated genes at logFC<1 were used to find overlaps with the genes 
containing ERV in its 3′ UTR (25 genes) (Supplementary Dataset 1).
SPARCS gene set enrichment analysis
The resulting list of SPARCS genes were used to perform ssGSEA analysis36 of 585 
carcinoma samples across CCLE (www.broadinstitute.org/CCLE) or 3219 samples from 
TCGA18 RNAseq datasets. In brief, in ssGSEA, gene expression values are first rank-
normalized ranked by their absolute expression, followed by calculation of an enrichment 
score (ES) of individual samples derived by evaluating the differences in the Empirical 
Cumulative Distribution Functions (ECDF) of the genes in the gene set (in this case the 
SPARCS gene set) relative to the remaining genes. A positive ES denotes significant overlap 
of the gene set with groups of genes at the top of the ranked list, while a negative ES denotes 
a significant overlap of the signature gene set with groups of genes at the bottom of the 
ranked list. These resulting ssGSEA scores for individual samples across CCLE or TCGA 
datasets were then sorted from highest to lowest and used to identify top genomic features 
associated with respective datasets. These included genes, mutations/copy number variations 
and pathways (MsigDB database). To quantify the degree of association, an information-
theoretic measure of Information Coefficient (IC)19 was calculated and an empirical 
permutation test for statistical significance calculations. The top 1000 genomic features 
significantly associated with the SPARCS signature are depicted in the heatmap.
ATAC-sequencing and analysis
We performed ATAC sequencing on H69 and H69AR cells according to 37. Briefly, we 
sorted 40–50,000 cells per biological replicate, which were then washed once in cold PBS 
and lysed in 50μL cold lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 
0.1% IGEPAL CA-630). Lysed nuclei were incubated in Tn5 transposition reaction mix and 
purified using MinElute Reaction Cleanup kit (Qiagen). ATAC-seq fragments from one set 
of replicates for H69 and H69AR cells were size selected for fragments between 115 and 
600 bp using Pippin Prep 2% Agarose Gel Cassettes and the Pippin Prep DNA Size 
Selection System (Sage Science). Post size-selection, ATAC libraries were amplified and 
Nextera sequencing primers ligated using Polymerase Chain Reaction (PCR). Finally, PCR 
primers were removed using Agencourt AMPure XP bead cleanup (Beckman Coulter/
Agencourt) and library quality was verified using a Tapestation machine. High quality 
‘multiplexed’ DNA libraries were sequenced on the Illumina HiSeq2000.
The ends of the paired-end fragments are used as cut sites and enriched peaks were called 
with MACS2 with following parameters (--nomodel --extsize 200 --shift -100 -g hs -B --
nolambda). For IGV visualization, shifted bedGraph were converted to wig files at 10bp 
resolution and normalized to read counts by wigmath tool of JavaGenomic toolkit.
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Statistical analyses
All graphs depict mean ± s.e.m unless otherwise indicated. Tests for differences between 
two groups were performed using two-tailed unpaired Student’s t-test or Mann-Whitney’s 
two-tailed test, as specified in the figure legends. Two-way ANOVA was performed where 
applicable using the Sidak post hoc test. P values were considered significant if less than 
0.05. Asterisks used to indicate significance correspond with: *p<0.05, **p<0.005, 
***p<0.001. GraphPad Prism7 was used for statistical analysis of experiments, data 
processing and presentation.
Data Availability
Expression Arrays Data from H69 and H69M cells are available at the Gene Expression 
Omnibus (GEO) under accession number GSE451209. ChIP-seq data for STAT1 and IRF1 
data on CD14+ monocytes are available at GEO database under accession number 
GSE4303635. Raw data for Figure 1j, Figures 3a–c, Figures 4a–d and Supplementary 
Figures 10–14 can be accessed in Supplementary Dataset 1–6.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Discovery of an IFN-inducible subclass of ERVs. (a) Immunoblot of pTBK1, TBK1, IKKε, 
pIRF3, pERK, ERK, pAKT, AKT and tubulin levels in H69 and H69M cells after 24 or 72 h 
culture. (b) Log-2 fold change cytokine/chemokine differences between H69M/H69 CM. (c) 
H&E and pTBK1 IHC of a patient-derived SCLC brain metastasis. Scale bar indicates 20 
μm. (d) Isotype control versus PD-L1 or CD44 surface expression on H69 and H69M cells 
± 200 ng/mL 24 h IFNγ stimulation (representative of n=3 biological replicates). (e) 
Immunoblot of pTBK1, TBK1, pERK, ERK, pAKT, AKT and β-actin levels in H69, H69M, 
H69M-PD-L1low, and H69M-PD-L1high cells. (f) Log-2 fold change cytokine/chemokines 
differences between H69M-PD-L1high or H69M-PD-L1low/H69 CM. (g) qRT-PCR of ERVs 
in H69M-PD-L1high normalized to H69M-PD-L1low cells. Numeric values on each bar 
represent the fold change in expression of a DNMT regulated ERV enriched panel11,12 of 
previously published ERVs. Error bars are mean ± s.e.m of n=3 biological replicates. 
TRIM22 promoter and antisense orientation of MLT1C49 in the 3′UTR are represented 
below the qRT-PCR graph. (h) qRT-PCR of CXCL10 and CCL2 in H69M PD-L1low cells 
transfected with pLX-307-GFP control or pLX_307-MLT1C49 construct for 72h. Mean ± 
s.e.m of n=3 biological replicates shown. (i) qRT-PCR of CXCL10 and CCL2 in H69M PD-
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L1high cells transfected with scrambled negative control siRNA or siRNAs specific for 
MLT1C49. Mean ± s.e.m of n=3 biological replicates shown. (j) Overlap of 3′UTR 
antisense ERVs with H69M upregulated genes (log-2 fold change relative to H69 >2) and 
table showing the fold change in expression of these genes/ERVs in H69M-PD-L1high 
normalized to H69M-PD-L1low cells. (k) Immunoblot of STING, MAVS, pTBK1, TBK1, 
pIRF3, IRF3, E-Cadherin, Vimentin and β-actin levels in H69M cells after CRISPR 
mediated deletion of MAVS and/or STING. (l) Log-2 fold change cytokine/chemokine 
differences in CM from H69M cells after CRISPR mediated deletion of MAVS and/or 
STING compared to sgCTRL (Scramble). (m) CXCL10 Luminex absolute levels (pg/mL) in 
Scramble, STING KO, MAVS KO and double KO (dKO) H69M cells. Mean ± s.e.m of n=2 
biological replicates shown.
*p<0.05; **p<0.005; ***p<0.001; n.s., not significant (All P values were calculated using an 
unpaired two-tailed Student’s t test).
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Figure 2. 
SPARCS expression is inducible and triggers positive feedback amplification. (a) Isotype 
control versus PD-L1 or CD44 surface expression on H69AR cells ± 200 ng/mL 24 h IFNγ 
stimulation (representative of n= 3 biological replicates). (b) Schematic of IFNγ pulse 
treatment (200 ng/mL) of H69 or H69AR cells. (c) qRT-PCR of MLT1C49 in H69 and 
H69AR cells ± 200 ng/mL IFNγ pulse – 24 h chase. Mean ± s.e.m of n=3 biological 
replicates shown (Two-way ANOVA; Sidak’s multiple comparisons tests). (d) ATAC-seq 
insertion tracks of H69 and H69AR cells around TRIM22, TRIM38 and PD-L1. 
Differentially accessible regions indicated with arrows. (e) Immunoblot of EZH2 and β-actin 
in H69, H69M and H69AR cells. (f) Log-2 fold change cytokine/chemokine differences 
between EZH2i treated H69 cells after IFNγ pulse, EZH2i treated cells, and IFNγ pulsed 
H69 cells relative to untreated control cells. *same as H69M-PD-L1high cytokine profile in 
Fig. 1f. (g) Log-2 fold change comparison of IFNγ induced expression of SPARCS ERVs in 
EZH2i treated H69 cells versus H69AR cells. (h) qRT-PCR of 36B4 control, MLT1C49, 
MLT1J and MLT1A in H69AR cells + 10 min IFNγ pulse - 24 h chase. RNA was treated 
with RNase A and immunoprecipitated with anti-dsRNA J2 antibody, values normalized 
against beta-actin. Mean ± s.e.m of n=3 biological replicates shown (Unpaired two-tailed 
Student’s t test). (i) Immunoblot of pTBK1, TBK1, pIRF3, IRF3, pSTAT1, STAT1 and β-
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actin levels in H69 and H69AR cells ± 200 ng/mL IFNγ 10 min pulse - 24 h chase. (j) qRT-
PCR of MLT1C49, IFN-β and CXCL10 in H69AR cells ± 10 min IFN-γ pulse - 24 h chase. 
Mean ± s.e.m of n=3 biological replicates shown (Unpaired two-tailed Student’s t test). (k) 
qRT-PCR and ELISA of CXCL10 in sgCTRL and sgMAVS-H69AR cells 72 h following 
Poly(I:C) transfection. Mean ± s.e.m of n=2 biological replicates shown (Unpaired two-
tailed Student’s t test). (l) Log-2 fold change cytokine/chemokine differences in CM 
between CRISPR-H69AR cells after 10 min IFNγ 10 ng/mL pulse relative to sgCTRL cells 
(Scramble). (m) CXCL10 ELISA in Scramble, STING KO, MAVS KO and dKO H69AR 
CM following 10 min IFNγ 10 ng/mL pulse and chase for 3 days. Mean ± s.e.m of n=3 
biological replicates shown (Unpaired two-tailed Student’s t test). (n) Photograph of 
representative excised tumors from sgCTRL and sgMAVS H69AR cells and tumor volumes 
measurements after 38 days of injection. Each data point represents mean ± s.e.m. tumor 
volumes (n=6 in sgCTRL group and n=6 in sgMAVS group; Two-way ANOVA; Sidak’s 
multiple comparisons tests).
*p<0.05; **p<0.005; ***p<0.001; n.s., not significant.
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Figure 3. 
Expression of SPARCS-containing genes across cancers. (a) ssGSEA of SPARCS-gene 
containing signature across TCGA (n=3602 tumors) and significantly associated gene sets 
grouped based on biological annotations. IC = information coefficient. FDR = false 
discovery rate. (b) Intersection of top 1000 genes co-regulated with SPARCS-containing 
gene signature in TCGA and CCLE datasets. MHC class I pathway genes in top 40 
highlighted in red, EMT related genes in blue and immune evasion markers in green. (c) 
Distribution of high versus low SPARCS-containing gene expression by TCGA cancer 
histology. (d) Immunoblot of AXL, MET, Vimentin, STING, MAVS and β-actin levels in 
cell lines with high, intermediate, or low SPARCS gene signature expression after 72 h 
culture. (e) qRT-PCR of MLT1C49, CXCL10, PD-L1 and CD44 in SPARCShigh and 
SPARCSlow cell lines ± IFNγ 10 min pulse - 24 h chase. p values indicated for comparison 
of SPARCShigh versus SPARCSlow groups. Mean ± s.e.m of n=2 biological replicates shown 
(Two-tailed Mann-Whitney U test).
*p<0.05; **p<0.005; ***p<0.001; n.s., not significant.
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Figure 4. 
SPARCS-containing gene expression is associated with adaptive and immune suppressive 
signatures. (a) ssGSEA of immune signatures in SPARCShigh and SPARCSlow primary 
tumors across TCGA (n=3602 tumors) and ranked based on q value significance. (b) 
Scatterplot representing difference in SPARCShigh vs SPARCSlow tumors of ssGSEA of 
immune signatures. –log10(FDR q-value) for a Student’s t test with equal variances for 
enrichment of ssGSEA of immune signatures in SPARCShigh vs SPARCSlow tumors shown 
on the y-axis. Signatures more highly represented in SPARCShigh tumors shown on right, 
versus SPARCSlow tumors shown on left. (c) q value significances of ssGSEA of immune 
signatures in SPARCShigh vs SPARCSlow tumors across TCGA. (d) TCGA RPKM values of 
CXCL10 and CCL2 in primary tumors grouped in SPARCShigh (n=50) and SPARCSlow 
(n=50) tumors. (e) Multiplexed immunofluorescence staining of cytokeratin, CD8 and CD4 
in KRAS mutant NSCLC human specimens used to generate PDOTS. Scale bar indicates 
100 μm. (f) Cytokine/chemokine heatmap for NSCLC PDOTS treated with Nivolumab 
(Nivo) (100 μg/mL), IFNγ (200 ng/mL), or Nivo + IFNγ plotted as Log-2 FC relative to 
control. * indicates values above assay for all conditions; # indicates max CXCL10 value 
used to calculate Log-2FC (g) CXCL10 Luminex absolute levels (pg/mL). Mean ± s.e.m of 
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duplicate samples shown. # indicates max CXCL10 values. (h) Phase contrast images and 
viability quantification analysis of NSCLC PDOTS performed on Day 6 following treatment 
with Nivolumab (100 μg/mL), IFNγ (200 ng/mL), or Nivo + IFNγ. Scale bar indicates 100 
μm.
*p<0.05; **p<0.005; ***p<0.001; n.s., not significant (All P values were calculated using an 
unpaired two-tailed Student’s t test).
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